“In the latest tussle over access to medicines, patient advocates in India are attempting to prevent Gilead Sciences from obtaining a patent for its forthcoming hepatitis C treatment, which is called sofosbuvir, over concerns that pricing will make the drug out of reach for many people.”
Learn more about how you can help build a more equitable system for all Notice: JavaScript is required for this content.